Search

everythinglearnresearchcommunity

for

Search:↓

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Kuntai capsules combined with nilestriol tablets effectively reduce perimenopausal symptoms and improve hormone levels.

The conclusion is that a new test was created to find substances that affect specific ion channels, and it works well for drug discovery.

Multicomponent crystals in microneedles improve drug delivery for hair loss treatment.

KF19418 promotes hair growth similarly to minoxidil but is not better in live mice.

Cosmetics with hinokitiol-loaded nanocapsules were found to effectively promote hair growth.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.

The document shows the state of pharmaceutical patents as of 1999, focusing on treatments for various diseases.

Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

The microneedle patches effectively treat allergic conjunctivitis with controlled, sustained release of medication.

MK-5108 is safe and shows potential against tumors, especially alone.

Tridax procumbens is a promising herb for developing safe, affordable plant-based medicines.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

Pharmacists play a crucial role in safe medication use and interdisciplinary collaboration is key to reducing antimicrobial resistance.

Tridax procumbens is a promising herb for developing safe, affordable plant-based medicines.

Double pulse dose terbinafine effectively treats kerion type of tinea capitis.

DiluCap improves how quickly minoxidil and finasteride dissolve and controls the release of melatonin and naltrexone.

Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.

Recent legal rulings favored Genentech, Teva, and upheld guidelines for patent term extensions.